Screener
Corcept Therapeutics CORT Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProfitLoss.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net income | $11,226 | $55,696 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Stock-based compensation | 52,459 | 40,853 |
| Accretion of marketable securities, net | (1,543) | (3,005) |
| Depreciation and amortization | 1,461 | 931 |
| Deferred income taxes | (10,229) | (31,469) |
| Changes in operating assets and liabilities: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's net income?
- Corcept Therapeutics (CORT) reported net income of $42.99M in Q2 2026.
- How has Corcept Therapeutics's net income changed year-over-year?
- Corcept Therapeutics's net income increased by 22.3% year-over-year, from $35.15M to $42.99M.
- What is the long-term trend for Corcept Therapeutics's net income?
- Over 4 years (2021 to 2025), Corcept Therapeutics's net income has grown at a -3.0% compound annual growth rate (CAGR), from $112.51M to $99.65M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.
Ask your AI about Corcept Therapeutics's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude